- Home
- SPRO vs RPTX Comparison
SPRO vs RPTX Comparison
Compare SPRO & RPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRO
- RPTX
- Stock Information
- Founded
- SPRO 2013
- RPTX 2016
- Country
- SPRO United States
- RPTX Canada
- Employees
- SPRO N/A
- RPTX N/A
- Industry
- SPRO Biotechnology: Pharmaceutical Preparations
- RPTX Biotechnology: Pharmaceutical Preparations
- Sector
- SPRO Health Care
- RPTX Health Care
- Exchange
- SPRO Nasdaq
- RPTX Nasdaq
- Market Cap
- SPRO 40.5M
- RPTX 38.3M
- IPO Year
- SPRO 2017
- RPTX 2020
- Fundamental
- Price
- SPRO $0.62
- RPTX $1.36
- Analyst Decision
- SPRO Buy
- RPTX Strong Buy
- Analyst Count
- SPRO 4
- RPTX 3
- Target Price
- SPRO $5.00
- RPTX $4.50
- AVG Volume (30 Days)
- SPRO 113.5K
- RPTX 502.5K
- Earning Date
- SPRO 05-13-2025
- RPTX 05-20-2025
- Dividend Yield
- SPRO N/A
- RPTX N/A
- EPS Growth
- SPRO N/A
- RPTX N/A
- EPS
- SPRO N/A
- RPTX N/A
- Revenue
- SPRO $47,977,000.00
- RPTX $53,477,000.00
- Revenue This Year
- SPRO N/A
- RPTX N/A
- Revenue Next Year
- SPRO N/A
- RPTX $7.14
- P/E Ratio
- SPRO N/A
- RPTX N/A
- Revenue Growth
- SPRO N/A
- RPTX 4.58
- 52 Week Low
- SPRO $0.51
- RPTX $0.89
- 52 Week High
- SPRO $1.72
- RPTX $4.29
- Technical
- Relative Strength Index (RSI)
- SPRO 41.34
- RPTX 59.23
- Support Level
- SPRO $0.64
- RPTX $1.31
- Resistance Level
- SPRO $0.75
- RPTX $1.48
- Average True Range (ATR)
- SPRO 0.05
- RPTX 0.10
- MACD
- SPRO -0.01
- RPTX 0.00
- Stochastic Oscillator
- SPRO 21.63
- RPTX 57.14
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.